Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS
The most common metabolic disease Chronic hyperglycemia Biochemical criteria Normal PrediabeticDiabetic FBS < 100 mg/dL mg/dL>126 mg/dL 2-h GTT <140 mg/dL mg/dL>200 mg/dL Hb A 1 C <5.6% %>6.5% 2
DM type I An autoimmune disease Onset during childhood Destruction of β-cells Treatment with insulin DM type II A progressive disorder Onset in adulthood Insulin resistance + progressive destruction of β-cells Early stages controlled with noninsulin antidiabetic drugs Later stages often require addition of insulin to drug regimen 3
InsulinsBiguanides α -Glucosidase inhibitors SulfonylureasThiazolidinediones 5
A small peptide hormone produced in the pancreas Synthesis as prohormone proinsulin (86 aa) Cleavage to insulin (51 aa) & C-peptide Proinsulin & C-peptide have no physiologic actions 6
Liver: ↑ Storage of glucose as glycogen ↓ Protein catabolism Skeletal muscle: ↑ Glucose transport into muscle cells ↑ Glycogen synthesis and protein synthesis Adipose tissue: ↑ Glucose transport into fat cells ↑ TG storage ↓ Intracellular lipolysis 7
DM I DM II DM emergencies Diabetic pregnant women 8
Different capacity to lower blood glucose. ◦ Rapid acting ◦ Short acting ◦ Intermediate acting ◦ Long acting 9
10
Lispro, aspart, glulisine Onset: <15 min Duration: 3-4 h rapid onsets and early peaks of activity 11
Lispro, aspart, glulisine Indications: ◦ control of postprandial glucose (immediately before a meal ) ◦ emergency treatment of uncomplicated diabetic ketoacidosis 12
Regular Onset: h Duration: 4-6 h 13
Regular Indications: ◦ emergencies of hyperglycemia (IV) ◦ ordinary maintenance regimens (SC) alone or mixed with intermediate preparations 14
Lente, Neutral Protamine Hagedorn (NPH) Onset: 1-4 h Duration : h 15
NPH insulin: exhibits a delayed onset and peak of action NPH insulin is often combined with regular and rapid-acting insulins 16
Glargine, Detemir, Ultralente Gradual release pattern from injection site Onset: 4 h Duration: h 17
Glargine, Detemir, Ultralente Effects: provide a peakless basal insulin level lasting more than 20 h Indication: control basal glucose levels without producing hypoglycemia 18
Hypoglycemia Insulin induced immunologic complication Injection pain Weight Gain 19
20
Insulin secretagogues (sulfonylureas) Biguanide (metformin) Thiazolidinediones (pioglitazone) α-glucosidase inhibitors (acarbose) Most commonly for TM II treatment 21
22
23
Insulin secretagogues MOA: ◦ Blockade of ATP-dependent K + channels (K ATP ) in β-cells of pancreas→membrane depolarization → ↑release of insulin Effects: ◦ ↑ Basal and postprandial insulin secretion ◦ No effect in patients with non-functional pancreatic β cells 24
25
1st generation: Tolbutamide, Chlorpropamide 2nd generation: Glibenclamide (Glyburide), Glipizide, Glimepiride ◦ More potent ◦ Used more commonly than the older agents 26
Indication: DM II Dosing: Once or twice daily Side effects: ◦ Hypoglycemia ◦ Weight gain 27
28
Metformin MOA: ◦ ↓hepatic glucose release ◦ ↓ gluconeogenesis ◦ Enhance peripheral glucose uptake & utilization ◦ ↑peripheral tissue sensitivity to insulin Effects: Enhancement of insulin action, decrease weight Depends upon:Presence of insulin Metformin is a euglycemic agent Slower action 29
Indications: ◦ DM II Dosing: Two to three times daily Side effects: Nausea ↓appetite & weight loss ◦ Lactic acidosis ◦ diarrhea 30
31
MOA: ◦ Carbohydrate analogs → α-glucosidase inhibition within the intestine → ↓glucose liberation → ↓intestinal glucose absorption → ↓(mild) blood glucose Acarbose & Miglitol 32
Effects: ◦ Delays carbohydrate absorption ◦ ↓Postprandial hyperglycemia ◦ No effect on fasting blood sugar and insulin release 33
DM II Prevent DM II in prediabetics Must be taken just before a meal Can be combined with other oral hypoglycemic agents Dosing: Three times daily (with each meal) 34
Flatulence Diarrhea Abdominal pain 35
36
Pioglitazone, Rosiglitazone 37
MOA: stimulation of nuclear receptors important for insulin action peroxisome proliferator-activated receptor-gamma nuclear receptor (PPAR-γ receptor) ↑target tissue sensitivity to insulin skeletal muscle and adipose tissues Effects: ↑glucose uptake in muscle and adipose tissue ↓both fasting and postprandial hyperglycemia Inhibition of hepatic gluconeogenesis (↓hepatic glucose output) Change in lipid metabolism and the distribution of body fat Shift of TG from non-adipose tissues to adipose tissue (↓serum TG) 38
Indications: ◦ DM II ◦ ↓ risk of DM II in high-risk patients Dosing: Once daily Side effects: ◦ Fluid retention presents as mild anemia and edema ◦ ↑ risk of MI (Rosiglitazone) 39
40